Friday 6-20-2014 Nanosphere Inc (NSPH) $NSPH opene
Post# of 7
Posted On: 06/20/2014 11:43:52 PM
Friday 6-20-2014 Nanosphere Inc (NSPH) $NSPH opened at 1.29 hitting the high price of 1.44 and a day low of 1.29 with a total volume of 1,427,988. NSPH had a previous close of 1.28 and has been seeing an average volume of 587,285.
Overall Average: 16% Sell
Recent stock forum discussions about NSPH http://investorshangout.com/search?q=NSPH&...mp;yt0=Go!
Hot Stock: Nanosphere, Shares Gain 7.8% (NSPH)
Comtex SmarTrend(R) - Fri Jun 20, 10:09AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's best performing low-priced stocks, up 7.8% to $1.38 on 1.1x average daily volume. Thus far today, Nanosphere has traded 746,000 shares, vs. average volume of 664,000 shares per day. The stock has outperformed the Dow (7.8% to the Dow's 0.3%) and outperformed the S&P 500 (7.8% to the S&P's 0.2%) during today's trading. (full story)
Biotech Stocks Technical Data -- Research on Navidea Biopharma, Alkermes, Nanosphere, and Organovo Holdings
PR Newswire - Tue Jun 10, 7:00AM CDT
The US markets on Monday, June 9, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,943.10, up 0.11% and the NASDAQ Composite closed at 4,336.24, up 0.34%. The S&P 500 finished the session 0.09% higher at 1,951.27. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 691.34, down 0.48%, whereas the index has advanced 3.44% in the last one month. Investor-Edge has initiated coverage on the following equities: Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), Alkermes PLC (NASDAQ: ALKS), Nanosphere Inc. (NASDAQ: NSPH) and Organovo Holdings Inc. (NYSE MKT: ONVO). Free technical research on NAVB, ALKS, NSPH and ONVO can be downloaded upon signing up at: (full story)
Twelve Studies Presented at ASM 2014 Highlight New Performance and Clinical Outcome Data Using Select Verigene Infectious Disease Tests
GlobeNewswire - Wed May 21, 7:15AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that twelve studies evaluating the performance and clinical impact of select Verigene(R) multiplex infectious disease tests have been presented at the 114 General Meeting of the American Society for Microbiology (asm2014), held this week in Boston, Massachusetts. (full story)
New Performance and Clinical Outcome Data from Twelve Studies Using Nanosphere's Infectious Disease Tests to be Presented at ASM 2014
GlobeNewswire - Fri May 16, 7:00AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that new performance and clinical outcome data for three Verigene(R) multiplex infectious disease tests will be presented at the 114 General Meeting of the American Society for Microbiology (asm2014), to be held in Boston, Massachusetts on May 17 - 20, 2014. (full story)
Studies Presented at ECCMID 2014 Highlight Accuracy and Potential Clinical Utility of Several Nanosphere Infectious Disease Tests
GlobeNewswire - Wed May 14, 7:17AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that six studies performed by various U.S. and international medical facilities have been presented at the 24 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) this week. These studies illustrate the unparalleled accuracy and demonstrated clinical utility of three Verigene(R) multiplex molecular infectious disease tests in both adult and pediatric patient populations. These include the Verigene Gram-Positive Blood Culture (BC-GP) (FDA-cleared; CE-IVD), Gram-Negative Blood Culture (BC-GN) (FDA-cleared; CE-IVD) and Enteric Pathogens (EP) (FDA clearance pending) Tests. (full story)
Top Gainers Pre-Market Notes -- Research on bebe stores, BioTelemetry, Axcelis Technologies, and Nanosphere
PR Newswire - Mon May 12, 10:30AM CDT
On Friday, May 9, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average advanced 0.20% to finish the day at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. During the session gains in the Consumer Discretionary, Health Care, and Consumer Staples sectors positively impacted the broader market, while some retraction came in from Utilities, Energy, and Financials sectors. A number of stocks saw large movements, including bebe stores inc. (NASDAQ: BEBE), BioTelemetry Inc. (NASDAQ: BEAT), Axcelis Technologies Inc. (NASDAQ: ACLS) and Nanosphere Inc. (NASDAQ: NSPH). Free technical research on BEBE, BEAT, ACLS and NSPH can be downloaded upon signing up at: (full story)
New Validation and Clinical Outcome Data From Several Studies Using Nanosphere's Infectious Disease Tests to be Presented at ECCMID 2014
GlobeNewswire - Thu May 08, 8:31AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that new validation and clinical outcome data for select Verigene(R) multiplex molecular infectious disease tests will be presented at the 24 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Barcelona, Spain on 10 - 13 May 2014. (full story)
Nanosphere Announces First Quarter Financial and Operating Results
GlobeNewswire - Wed May 07, 9:13AM CDT
Corporate Highlights and Business Guidance: (full story)
Global Nanomedicine Market Forecasts Report 2013-2019
M2 - Tue Apr 29, 3:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47pbsh/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. The emergence of nanomedicine and the application of nanomaterials in the healthcare industry will bring about groundbreaking improvements to the current therapeutic and diagnostic scenario.Some of the drivers of this market include increasing research funding, rising government support, improved regulatory framework, technological know-how and rising prevalence of chronic diseases such as diabetes, cancers, obesity, kidney disorders, orthopedic diseases and others. The global nanomedicine market is categorized into six segments on the basis of application, namely neurology, cardiovascular, anti-inflammatory, anti-infective, oncology and others. Oncology held majority of the market share in 2012 on account of following factors: - Presence of high number of commercialized nanomedicine products in the market - Improved bioavailability and efficacy of the tumor specific nanomedicine enabling targeted drug delivery - Rise in nanomedicine drug formulations replacing conventional drug formulations in cancer treatment However, the global market for cardiovascular segment is expected to grow at the fastest pace owing to increasing prevalence of cardiovascular diseases demanding drugs with improved efficacy and therapeutic properties. Furthermore, realizing the importance and benefits of nanomedicine, researchers and manufacturers are striving to develop products with improved therapeutic properties in the cardiovascular segment. The North American nanomedicine market held the majority of global market share in 2012 because of the rapidly growing nanomedicine market in the Asia-Pacific, Latin American and African region, presence of large number of patented nanomedicine products and favorable regulatory framework in the region.In addition, the presence of sophisticated healthcare infrastructure supports development of advanced products such as nano probes, nanorobots, monoclonal antibody based immunoassays and nanoparticle based imaging agents for early detection of diseases. However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as China, India and other economies in the region.China is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region. The global nanomedicine market is categorized into the following segments: Application - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/47...nomedicine (full story)
Nanosphere to Release First Quarter Results and Host Investor Conference Call on Wednesday, May 7, 2014
GlobeNewswire - Thu Apr 17, 7:00AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it will report its results for the first quarter of 2014 on Wednesday, May 7, 2014. The company will also hold a live investor conference call and webcast at 10:00am Eastern/7:00am Pacific. (full story)
Prana Biotechnology Stock Hits New Low
ACCESSWIRE - Wed Apr 16, 9:47AM CDT
Prana Biotechnology (NASDAQ
RAN) share value has been tumbling over the last month, closing at $1.74 Apr. 15, down 15 cents from the previous day's close of $1.89. (full story)
Nanosphere Down 5.8%, Shares Slide into the Red (NSPH)
Comtex SmarTrend(R) - Mon Apr 14, 12:46PM CDT
Nanosphere (NASDAQ:NSPH) is one of today's worst performing low-priced stocks, down 5.8% to $1.92 on 1.0x average daily volume. Nanosphere has traded 741,000 shares thus far today, vs. average volume of 728,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's 0.9%) and underperformed the S&P 500 (-5.8% to the S&P's 0.8%) during today's trading. (full story)
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. (full story)
Nanosphere signs USD30m purchase deal with Aspire Capital
M2 - Wed Mar 19, 8:23AM CDT
Molecular diagnostics company Nanosphere (NasdaqGM:NSPH) reported on Tuesday the launch of a USD30m purchase agreement with Aspire Capital Fund. (full story)
Nanosphere Enters Into $30 Million Common Stock Purchase Agreement With Aspire Capital
GlobeNewswire - Tue Mar 18, 4:00PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced it has entered into a Common Stock Purchase Agreement with Aspire Capital Fund, LLC ("Aspire Capital"
, whereby Nanosphere has the right to sell up to $30 million of shares of its common stock to Aspire Capital under certain conditions from time to time. Aspire Capital is an existing Nanosphere shareholder, having invested in the Company's most recent underwritten public offering in September 2013. (full story)
Nanosphere to Present at the 26th Annual ROTH Conference
GlobeNewswire - Fri Mar 07, 2:59AM CST
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that an overview of the company's business and commercial strategy will be given by Roger Moody, Chief Financial Officer, at the 26 Annual ROTH Conference, being held at the Ritz Carlton in Dana Point, California from March 9-12, 2014. (full story)
Nanosphere to Host Investor Day on March 20th in New York
GlobeNewswire - Mon Mar 03, 7:00AM CST
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it will host an Investor Day on Thursday, March 20, 2014, beginning at 8:00am Eastern Time, in New York City. Nanosphere's executive management team will provide an overview of the Company's strategies to drive long-term growth and enhance shareholder value, and an industry key opinion leader will offer perspective on the value of Nanosphere's molecular diagnostic offerings. (full story)
Nanosphere to Present at the 34th Annual Cowen & Company Health Care Conference
Marketwire - Wed Feb 26, 12:51PM CST
Nanosphere, Inc. (NASDAQ: NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that that an overview of the company's business and commercial strategy will be given by Michael McGarrity, President and Chief Executive Officer, at the Cowen & Company 34th Annual Health Care Conference, being held at the Boston Marriott Copley Place in Boston, Massachusetts, March 3-5, 2014. (full story)
Worldwide Nanomedicine Market Report 2013-2019: Neurology, Cardiovascular, Anti-inflammatory, Anti-infective & Oncology Applications
M2 - Wed Feb 19, 9:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4bpxtn/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019. The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report. The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world. The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period. The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nanomedicine market is categorized into the following segments: - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/4b...nomedicine (full story)
Overall Average: 16% Sell
Recent stock forum discussions about NSPH http://investorshangout.com/search?q=NSPH&...mp;yt0=Go!
Hot Stock: Nanosphere, Shares Gain 7.8% (NSPH)
Comtex SmarTrend(R) - Fri Jun 20, 10:09AM CDT
Nanosphere (NASDAQ:NSPH) is one of today's best performing low-priced stocks, up 7.8% to $1.38 on 1.1x average daily volume. Thus far today, Nanosphere has traded 746,000 shares, vs. average volume of 664,000 shares per day. The stock has outperformed the Dow (7.8% to the Dow's 0.3%) and outperformed the S&P 500 (7.8% to the S&P's 0.2%) during today's trading. (full story)
Biotech Stocks Technical Data -- Research on Navidea Biopharma, Alkermes, Nanosphere, and Organovo Holdings
PR Newswire - Tue Jun 10, 7:00AM CDT
The US markets on Monday, June 9, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,943.10, up 0.11% and the NASDAQ Composite closed at 4,336.24, up 0.34%. The S&P 500 finished the session 0.09% higher at 1,951.27. During the trading session, six out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 691.34, down 0.48%, whereas the index has advanced 3.44% in the last one month. Investor-Edge has initiated coverage on the following equities: Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), Alkermes PLC (NASDAQ: ALKS), Nanosphere Inc. (NASDAQ: NSPH) and Organovo Holdings Inc. (NYSE MKT: ONVO). Free technical research on NAVB, ALKS, NSPH and ONVO can be downloaded upon signing up at: (full story)
Twelve Studies Presented at ASM 2014 Highlight New Performance and Clinical Outcome Data Using Select Verigene Infectious Disease Tests
GlobeNewswire - Wed May 21, 7:15AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that twelve studies evaluating the performance and clinical impact of select Verigene(R) multiplex infectious disease tests have been presented at the 114 General Meeting of the American Society for Microbiology (asm2014), held this week in Boston, Massachusetts. (full story)
New Performance and Clinical Outcome Data from Twelve Studies Using Nanosphere's Infectious Disease Tests to be Presented at ASM 2014
GlobeNewswire - Fri May 16, 7:00AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that new performance and clinical outcome data for three Verigene(R) multiplex infectious disease tests will be presented at the 114 General Meeting of the American Society for Microbiology (asm2014), to be held in Boston, Massachusetts on May 17 - 20, 2014. (full story)
Studies Presented at ECCMID 2014 Highlight Accuracy and Potential Clinical Utility of Several Nanosphere Infectious Disease Tests
GlobeNewswire - Wed May 14, 7:17AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that six studies performed by various U.S. and international medical facilities have been presented at the 24 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) this week. These studies illustrate the unparalleled accuracy and demonstrated clinical utility of three Verigene(R) multiplex molecular infectious disease tests in both adult and pediatric patient populations. These include the Verigene Gram-Positive Blood Culture (BC-GP) (FDA-cleared; CE-IVD), Gram-Negative Blood Culture (BC-GN) (FDA-cleared; CE-IVD) and Enteric Pathogens (EP) (FDA clearance pending) Tests. (full story)
Top Gainers Pre-Market Notes -- Research on bebe stores, BioTelemetry, Axcelis Technologies, and Nanosphere
PR Newswire - Mon May 12, 10:30AM CDT
On Friday, May 9, 2014, the NASDAQ Composite ended at 4,071.87, up 0.50%, the Dow Jones Industrial Average advanced 0.20% to finish the day at 16,583.34, and the S&P 500 closed at 1,878.48, up 0.15%. During the session gains in the Consumer Discretionary, Health Care, and Consumer Staples sectors positively impacted the broader market, while some retraction came in from Utilities, Energy, and Financials sectors. A number of stocks saw large movements, including bebe stores inc. (NASDAQ: BEBE), BioTelemetry Inc. (NASDAQ: BEAT), Axcelis Technologies Inc. (NASDAQ: ACLS) and Nanosphere Inc. (NASDAQ: NSPH). Free technical research on BEBE, BEAT, ACLS and NSPH can be downloaded upon signing up at: (full story)
New Validation and Clinical Outcome Data From Several Studies Using Nanosphere's Infectious Disease Tests to be Presented at ECCMID 2014
GlobeNewswire - Thu May 08, 8:31AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that new validation and clinical outcome data for select Verigene(R) multiplex molecular infectious disease tests will be presented at the 24 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held in Barcelona, Spain on 10 - 13 May 2014. (full story)
Nanosphere Announces First Quarter Financial and Operating Results
GlobeNewswire - Wed May 07, 9:13AM CDT
Corporate Highlights and Business Guidance: (full story)
Global Nanomedicine Market Forecasts Report 2013-2019
M2 - Tue Apr 29, 3:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47pbsh/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. The emergence of nanomedicine and the application of nanomaterials in the healthcare industry will bring about groundbreaking improvements to the current therapeutic and diagnostic scenario.Some of the drivers of this market include increasing research funding, rising government support, improved regulatory framework, technological know-how and rising prevalence of chronic diseases such as diabetes, cancers, obesity, kidney disorders, orthopedic diseases and others. The global nanomedicine market is categorized into six segments on the basis of application, namely neurology, cardiovascular, anti-inflammatory, anti-infective, oncology and others. Oncology held majority of the market share in 2012 on account of following factors: - Presence of high number of commercialized nanomedicine products in the market - Improved bioavailability and efficacy of the tumor specific nanomedicine enabling targeted drug delivery - Rise in nanomedicine drug formulations replacing conventional drug formulations in cancer treatment However, the global market for cardiovascular segment is expected to grow at the fastest pace owing to increasing prevalence of cardiovascular diseases demanding drugs with improved efficacy and therapeutic properties. Furthermore, realizing the importance and benefits of nanomedicine, researchers and manufacturers are striving to develop products with improved therapeutic properties in the cardiovascular segment. The North American nanomedicine market held the majority of global market share in 2012 because of the rapidly growing nanomedicine market in the Asia-Pacific, Latin American and African region, presence of large number of patented nanomedicine products and favorable regulatory framework in the region.In addition, the presence of sophisticated healthcare infrastructure supports development of advanced products such as nano probes, nanorobots, monoclonal antibody based immunoassays and nanoparticle based imaging agents for early detection of diseases. However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as China, India and other economies in the region.China is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region. The global nanomedicine market is categorized into the following segments: Application - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/47...nomedicine (full story)
Nanosphere to Release First Quarter Results and Host Investor Conference Call on Wednesday, May 7, 2014
GlobeNewswire - Thu Apr 17, 7:00AM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it will report its results for the first quarter of 2014 on Wednesday, May 7, 2014. The company will also hold a live investor conference call and webcast at 10:00am Eastern/7:00am Pacific. (full story)
Prana Biotechnology Stock Hits New Low
ACCESSWIRE - Wed Apr 16, 9:47AM CDT
Prana Biotechnology (NASDAQ
RAN) share value has been tumbling over the last month, closing at $1.74 Apr. 15, down 15 cents from the previous day's close of $1.89. (full story) Nanosphere Down 5.8%, Shares Slide into the Red (NSPH)
Comtex SmarTrend(R) - Mon Apr 14, 12:46PM CDT
Nanosphere (NASDAQ:NSPH) is one of today's worst performing low-priced stocks, down 5.8% to $1.92 on 1.0x average daily volume. Nanosphere has traded 741,000 shares thus far today, vs. average volume of 728,000 shares per day. The stock has underperformed the Dow (-5.8% to the Dow's 0.9%) and underperformed the S&P 500 (-5.8% to the S&P's 0.8%) during today's trading. (full story)
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. (full story)
Nanosphere signs USD30m purchase deal with Aspire Capital
M2 - Wed Mar 19, 8:23AM CDT
Molecular diagnostics company Nanosphere (NasdaqGM:NSPH) reported on Tuesday the launch of a USD30m purchase agreement with Aspire Capital Fund. (full story)
Nanosphere Enters Into $30 Million Common Stock Purchase Agreement With Aspire Capital
GlobeNewswire - Tue Mar 18, 4:00PM CDT
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced it has entered into a Common Stock Purchase Agreement with Aspire Capital Fund, LLC ("Aspire Capital"
, whereby Nanosphere has the right to sell up to $30 million of shares of its common stock to Aspire Capital under certain conditions from time to time. Aspire Capital is an existing Nanosphere shareholder, having invested in the Company's most recent underwritten public offering in September 2013. (full story) Nanosphere to Present at the 26th Annual ROTH Conference
GlobeNewswire - Fri Mar 07, 2:59AM CST
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that an overview of the company's business and commercial strategy will be given by Roger Moody, Chief Financial Officer, at the 26 Annual ROTH Conference, being held at the Ritz Carlton in Dana Point, California from March 9-12, 2014. (full story)
Nanosphere to Host Investor Day on March 20th in New York
GlobeNewswire - Mon Mar 03, 7:00AM CST
Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that it will host an Investor Day on Thursday, March 20, 2014, beginning at 8:00am Eastern Time, in New York City. Nanosphere's executive management team will provide an overview of the Company's strategies to drive long-term growth and enhance shareholder value, and an industry key opinion leader will offer perspective on the value of Nanosphere's molecular diagnostic offerings. (full story)
Nanosphere to Present at the 34th Annual Cowen & Company Health Care Conference
Marketwire - Wed Feb 26, 12:51PM CST
Nanosphere, Inc. (NASDAQ: NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced that that an overview of the company's business and commercial strategy will be given by Michael McGarrity, President and Chief Executive Officer, at the Cowen & Company 34th Annual Health Care Conference, being held at the Boston Marriott Copley Place in Boston, Massachusetts, March 3-5, 2014. (full story)
Worldwide Nanomedicine Market Report 2013-2019: Neurology, Cardiovascular, Anti-inflammatory, Anti-infective & Oncology Applications
M2 - Wed Feb 19, 9:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4bpxtn/nanomedicine) has announced the addition of the "Nanomedicine Market - Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013 - 2019" report to their offering. This report includes market estimations for the nanomedicine market for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 - 2019. The overall nanomedicine market is segmented on the basis of application and geography and the market estimations for each of these segments, in terms of USD billion, is provided in this report. The nanomedicine market, by applications is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and rest of the world. The global trends such as drivers, restraints and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report., with a view on impact of these factors on market growth along the course of the forecast period. The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global nanomedicine market is categorized into the following segments: - Neurology - Cardiovascular - Anti-Inflammatory - Anti-Infectives - Oncology - Others Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Global Nanomedicine Market Overview Chapter 4 Global Nanomedicine Market, by Applications Chapter 5 Global Nanomedicine Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Abbott Laboratories - Celgene Corporation - CombiMatrix Corporation - GE Healthcare - Johnson & Johnson - Mallinckrodt plc. - Merck & Company Inc. - Nanosphere, Inc. - Pfizer Inc. - Sigma-Tau Pharmaceuticals Inc. - Teva Pharmaceutical Industries Ltd. - UCB SA For more information visit http://www.researchandmarkets.com/research/4b...nomedicine (full story)
(0)
(0)Nanosphere Inc. (NSPH) Stock Research Links
Scroll down for more posts ▼